NO20072169L - Formuleringer av (1,4)diazepino(6,7,IJ)kinolinderivater - Google Patents

Formuleringer av (1,4)diazepino(6,7,IJ)kinolinderivater

Info

Publication number
NO20072169L
NO20072169L NO20072169A NO20072169A NO20072169L NO 20072169 L NO20072169 L NO 20072169L NO 20072169 A NO20072169 A NO 20072169A NO 20072169 A NO20072169 A NO 20072169A NO 20072169 L NO20072169 L NO 20072169L
Authority
NO
Norway
Prior art keywords
diazepino
formulations
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
NO20072169A
Other languages
English (en)
Norwegian (no)
Inventor
Wendy Ann Dulin
Yanning Lin
Mannching S Ku
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20072169L publication Critical patent/NO20072169L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20072169A 2004-11-05 2007-04-26 Formuleringer av (1,4)diazepino(6,7,IJ)kinolinderivater NO20072169L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62528004P 2004-11-05 2004-11-05
PCT/US2005/040290 WO2006052887A1 (en) 2004-11-05 2005-11-04 Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives

Publications (1)

Publication Number Publication Date
NO20072169L true NO20072169L (no) 2007-07-24

Family

ID=35841773

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072169A NO20072169L (no) 2004-11-05 2007-04-26 Formuleringer av (1,4)diazepino(6,7,IJ)kinolinderivater

Country Status (19)

Country Link
US (1) US20060110451A1 (es)
EP (1) EP1807088A1 (es)
JP (1) JP2008519057A (es)
KR (1) KR20070084010A (es)
CN (1) CN101094675A (es)
AR (1) AR051946A1 (es)
AU (1) AU2005304758A1 (es)
BR (1) BRPI0517060A (es)
CA (1) CA2586124A1 (es)
GT (1) GT200500318A (es)
IL (1) IL182800A0 (es)
MX (1) MX2007005478A (es)
NO (1) NO20072169L (es)
PE (1) PE20060944A1 (es)
RU (1) RU2007114079A (es)
SV (1) SV2006002293A (es)
TW (1) TW200630100A (es)
WO (1) WO2006052887A1 (es)
ZA (1) ZA200703623B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
PE20080126A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
AU2015330937B2 (en) * 2014-10-08 2021-07-15 Theriva Biologics, Inc. Beta-lactamase formulations and uses thereof
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
CN105920017B (zh) * 2016-06-08 2018-06-05 广州嘉德乐生化科技有限公司 一种治疗单纯性肥胖症的药物组合物及其用途
US11311573B2 (en) 2016-11-30 2022-04-26 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
CN111743976A (zh) * 2020-07-03 2020-10-09 广西医科大学 一种二氧化硅气凝胶在制备治疗骨关节炎药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH02180885A (ja) * 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6761904B2 (en) * 2000-03-31 2004-07-13 Nycomed Austria Gmbh Pharmaceutical kit comprising midodrine as active drug substance
AR031196A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US7141563B2 (en) * 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
AR031195A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US6414144B1 (en) * 2000-11-03 2002-07-02 Wyeth Process for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi] indole derivatives
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
EP1343791A2 (en) * 2000-12-20 2003-09-17 Bristol-Myers Squibb Company Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
JP2005501092A (ja) * 2001-08-06 2005-01-13 ファルマシア・アンド・アップジョン・カンパニー 治療上有用な四環リガンド
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
AU2003303210A1 (en) * 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
PE20080126A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines

Also Published As

Publication number Publication date
MX2007005478A (es) 2007-05-24
SV2006002293A (es) 2006-10-13
CN101094675A (zh) 2007-12-26
CA2586124A1 (en) 2006-05-18
AR051946A1 (es) 2007-02-21
PE20060944A1 (es) 2006-10-27
ZA200703623B (en) 2009-10-28
TW200630100A (en) 2006-09-01
EP1807088A1 (en) 2007-07-18
WO2006052887A1 (en) 2006-05-18
AU2005304758A1 (en) 2006-05-18
US20060110451A1 (en) 2006-05-25
JP2008519057A (ja) 2008-06-05
IL182800A0 (en) 2007-09-20
KR20070084010A (ko) 2007-08-24
RU2007114079A (ru) 2008-12-10
BRPI0517060A (pt) 2008-09-30
GT200500318A (es) 2006-06-13

Similar Documents

Publication Publication Date Title
NO20072169L (no) Formuleringer av (1,4)diazepino(6,7,IJ)kinolinderivater
TW200716589A (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
NO20093060L (no) Spirosykliske sykloheksanderivater
AU2006320945A8 (en) Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
EP2698160A3 (en) Organic compounds
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
NO20081365L (no) Ny krystallinsk form av et pyridazino[4,5-b]indolderivat
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
IL190510A (en) Derivatives of pyrzolo [a-1,5] pyrimidine-7-illamine supported by the halogen in position 6 and (1 or 2) of methylpyrzole-4-ram in position 3, and pharmaceutical preparations containing them
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
DK1470124T3 (da) 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
DK1699795T3 (da) Substituerede 8'-pyri(mi)dinyldihydrospiro[cycloalkylamin]-pyrimido[1,2-a]pyrimidin-6-onderivater
NO20043508L (no) Pyrrolopyrimidin og pyrrolopyridinderivater substituert med syklisk aminogruppe
ATE472548T1 (de) Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO20041142L (no) Subsitituerte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyrimidinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivater for neurodegenerative lidelser
TW200513461A (en) Organische verbindungen
DE60335094D1 (de) Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel
ATE460396T1 (de) N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinon, verfahren zu dessen herstellung und pharmazeutische verwendung
IL175724A0 (en) Tricyclic imidazopyridine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
SI1560830T1 (sl) Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
ATE425976T1 (de) Pyrido[2,3-d]pyrimidin-7-carbonsaurederivate, deren herstellung und deren verwendung als pharmazeutische mittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application